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Cedric Carli,1 Martin Giroux,1 Jean-Sebastien Delisle1,2,3Transforming growth factor (TGF)-b is a pleiotropic cytokine with widespread and profound effects on
immune cells. Consequently, it has generated considerable interest in relation to the immunologic outcomes
after allogeneic hematopoietic cell transplantation. The TGF-b pathway has been shown to be an important
modulator of alloimmunity, with direct consequences on graft-versus-host disease pathophysiology and
graft-versus-tumor response. The TGF-b–related effects can be both beneficial and detrimental to the
host, underscoring the complexity of TGF-b biology. This article reviews the evidence linking TGF-b to allo-
immune responses in allogeneic hematopoietic cell transplantation and highlights foreseeable strategies
that would maximize the beneficial effects of TGF-b pathway modulation on both graft-versus-host disease
pathophysiology and the graft-versus-tumor effect.
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FibrogenesisINTRODUCTION
Allogeneic hematopoietic cell transplantation
(AHCT) has been a major clinical and conceptual
breakthrough in the treatment of blood cancers and
remains the only curative treatment modality for
a wide range of hematopoietic malignancies. In many
instances, the added benefit of AHCT over chemo-
therapy and/or radiation derives from the so-called
‘graft-versus-tumor’ (GVT) effect, a direct conse-
quence of the alloimmune response occurring
posttransplantation [1,2]. The activation of donor-
type T lymphocytes by histocompatibility antigens
after AHCT triggers a strong immune response that
can lead to tumor cell eradication. However, the
alloimmune response against the host often causes
considerable collateral damage in the form of
graft-versus-host disease (GVHD) [3,4]. GVHD
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6/j.bbmt.2012.01.020responsible for substantial mortality and morbidity
after transplantation [5]. Moreover, both GVHD itself
and the immunosuppressive medications used for its
prevention and treatment predispose patients to life-
threatening infections [6]. Therefore, the need to
understand the biological underpinnings of the GVT
effect and GVHD, to maximize the former and limit
the latter, is repeated as a leitmotiv in the field of
AHCT.
The roles of several cytokines have been studied in
both human AHCT and animal models with the aim of
better understanding how alloimmunity is orches-
trated.Transforming growth factor (TGF)-b is a pleio-
tropic cytokine involved in a wide spectrum of
biological processes, including cancer, tissue model-
ing, and immunity [7,8]. Our knowledge of TGF-b’s
role in AHCT is growing, and it is considered to
likely regulate all pertinent immune-related outcomes,
ranging from alloreactivity to host defense against
infection. Current evidence suggests thatTGF-bmod-
ulates both the beneficial and detrimental conse-
quences of the antihost response. Thus, targeting
TGF-b in clinical AHCT may show great promise
but also presents a formidable challenge.REGULATION OF IMMUNE CELLS BY TGF-b
The interest in TGF-b as a likely modulator of
alloimmune reactions stemmed from a wealth of data
showing the essential function of TGF-b in main-
taining peripheral tolerance [9-11]. TGF-b– and
TGF-b receptor (TGF-bR)–deficient animals die1329
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disease early in life. Accordingly, it was later found that
TGF-b signaling is constitutively active in quiescent T
cells and down regulated on T cell activation [12,13].
The most commonly described effects of TGF-b in
T cells include blunting of cell proliferation [14], inhi-
bition of cytotoxic mechanisms [15], blockade of Th1
and Th2 skewing [16,17], and contribution to
regulatory T cell (Treg) and Th17 differentiation
[18,19]. The discovery that TGF-b could promote
Th17 differentiation, in most circumstances an
inflammatory subset of CD4 T cells, highlights the
determining importance of context in TGF-
b biology. The current Th17 development model
states that TGF-b is essential to early Th17
differentiation but that IL-6 signals are required to
crystallize the Th17 fate over that of induced Tregs,
which is also TGF-b and context dependent [20].
Therefore, the ultimate output of TGF-b signaling
in a given cell type depends on the integration of sev-
eral other signals and variables, including state of cell
differentiation, timing, and dose [21,22]. As an
illustration of such versatility, it has been suggested
that TGF-b conveys prosurvival signals to naive
CD8 T cells [18] but promotes activated short-lived
effector CD8 T cell apoptosis by down regulating
Bcl-2 expression [23].
The immunoregulatory properties ofTGF-b reach
well beyond T cell subsets: B lymphocytes, natural
killer (NK) cells, dendritic cells, macrophages and
granulocytes are also under its influence. Analogous
to what is observed in T cells, B lymphocyte prolifer-
ation [24] and NK cell cytotoxicity [25,26] are
blunted by TGF-b. However, TGF-b favors IgA
production by B lymphocytes [27] and thus contrib-
utes to mucosal immune homeostasis. Likewise,
TGF-b participates in skin immunity as an essential
cytokine in the ontogeny of Langerhans cells [28].
Nonetheless, most of the available evidence strongly
suggests that TGF-b is a potent inhibitor of dendritic
cell maturation, thereby enforcing peripheral toler-
ance but negatively affecting the development of pro-
ductive adaptive responses [8]. In myeloid cell
biology, murine studies have shown that TGF-b re-
stricts myeloid cell growth and inflammation [29,30].
Macrophage activation and microbicidal mechanisms
are potently inhibited by TGF-b. It has been shown
that TGF-b induces scavenger receptor down-
regulation [31] and negatively regulates Toll-like
receptor signaling by causing MyD88 degradation
[32]. Whether TGF-b directly polarizes macrophages
away from a proinflammatory M1 phenotype to an
immunoregulatory M2 phenotype is unclear, but a re-
cent report identified TGF-b signaling as a molecular
switch that converts inflammatory neutrophils to
protumoral regulatory neutrophils within cancer envi-
ronments [33]. Notwithstanding the immunoregula-tory roles of TGF-b on myeloid cells, monocyte and
neutrophil recruitment to sites of tissue injury is pro-
moted by TGF-b, which acts as a chemotactic signal
[34,35]. Finally, myeloid subsets not only respond to
TGF-b but are also important TGF-b producers
[36], which contributes to their role in the resolution
of inflammation, tissue repair, and scarring. This last
aspect, particularly the cardinal role of TGF-b in the
physiological and pathogenic fibrogenic response after
tissue injury (reviewed in [37-40]), is highly relevant to
both GVHD and cancer biology.TGF-b AND FIBROGENESIS
After tissue injury, several stimuli can trigger the
release of TGF-b. In concert with other profibrogenic
stimuli, such as platelet-derived growth factor [41],
TGF-b will orchestrate the synthesis and release of
collagen and other extracellular matrix components.
It is now recognized that cells of themyelomonotic lin-
eage (resident or recruited) are the principal producers
of TGF-b in fibrogenesis [37]. Several genes encoding
collagen proteins are direct downstream targets of
TGF-b signaling and can be expressed in collagen-
producing cells [42]. In the context of tissue injury,
several cell types belonging to the mesenchymal line-
age, such as myofibroblasts, are differentiated in situ
from fibroblasts or mobilized from distant sites to pro-
duce extracellular matrix proteins [43]. An additional
role of TGF-b is in the mediation of this differentia-
tion. Moreover, TGF-b is central to a process called
epitheliomesenchymal transition, whereby cells of
epithelial origin undergo a phenotypic and functional
transition to become mesenchymal-type cells. In this
process, the epithelial cells lose their polarity and the
cell–cell interactions typical of epithelia to become
motile, elongated, and apolar cells [44-46]. These
newly converted mesenchymal cells can further
amplify the fibrotic response. Although early fibrotic
changes can be reversed, notably through resolution
of the inflammatory process and secretion of
extracellular matrix-degrading enzymes, chronic tissue
injury leads to permanent remodeling.VERSATILITYAND REGULATION OF
TGF-b SIGNALING
The TGF-b family of ligands appeared before the
divergence between arthropods and vertebrates, more
than 1 billion years ago [47]. It comprises more than
40 members, with several of them conserved through
evolution. In lymphoid tissues, TGF-b1 is the most
abundant of 3 isoforms (TGF-b1, TGF-b2, and
TGF-b3) and is initially synthesized as a precursor
protein. Hematopoietic cells are the main source of
TGF-b [36,48], but stromal cells, including
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TGF-b production. TGF-b is synthesized as a propep-
tide and processed in the Golgi apparatus, where the
proregion, latency-associated peptide is cleaved by
furin-like peptidases. Nonetheless, the latency-
associated peptide remains noncovalently attached to
TGF-b. As a homodimeric latent form, TGF-b will
usually bind to the latent TGF-binding protein [50]
for efficient secretion and attachment to the extracellu-
lar matrix, which becomes a reservoir of inactive TGF-
b [51,52]. Through the action of several molecules,
including reactive oxygen species, integrins, and
proteases, TGF-b is displaced or liberated from the
latency-associated peptide and latent TGF-binding
protein to become available for its ubiquitously
expressed receptor. Thus, the regulation of TGF-
b availability relies on both de novo synthesis and
liberation from the extracellular milieu. The TGF-
b receptor (TGF-bR) is a tetrameric receptor com-
posed of 2 TGF-bR I chains (TGF-bRI) and 2
TGF-bR II chains (TGF-bRII), both of which are ser-
ine/threonine kinases. TGF-b initially binds TGF-
bRII chains, which then recruit and transphophorylate
TGF-bRI. TGF-bRI then phosphorylates and acti-
vates downstream signaling molecules [21,53]. The
so-called ‘canonical’ TGF-b signaling pathway in-
volves Mother against decapentaplegic homolog
(SMAD) 2 and SMAD3, which are recruited and phos-
phorylated near their C-terminus by TGF-bRI. Once
activated, SMAD2 and SMAD3 can form hetero-
trimers with SMAD4 or transcriptional intermediary
factor 1-g in the cytosol [22,54]. The SMAD
complexes migrate to the nucleus and modulate the
transcription of hundreds of genes.
Depending on cell type and differentiation status,
the TGF-b/SMAD axis controls a wide variety of bio-
logical processes, ranging from proliferation and
differentiation to apoptosis. A determining aspect
of SMAD-mediated transcription regulation is the re-
quirement for coactivators and corepressors, given
that SMAD complexes are poor transcriptional modu-
lators by themselves. Thus, the result of TGF-b signal-
ing on gene expression is highly dependent on the
presence of other molecules, which in itself provides
a substratum to explain the cell and context specificity
of TGF-b signaling [21,22]. Moreover, SMAD
proteins can undergo significant posttranslational
modifications that will affect their biological
function. Several of these modifications are tributary
of other signaling pathway activity. A well-known ex-
ample is the phosphorylation of SMAD proteins by
members of themitogen-activated protein kinase path-
way (at different sites than those phosphorylated by
TGF-bRI), which interferes with their translocation
to the nucleus [55]. Further accounting for the diversity
of TGF-b’s effects, SMAD2 and SMAD3 were found
to mediate different effects despite their shared activa-tion mechanism and partnership with SMAD4 and
transcriptional intermediary factor 1-g. SMAD2 defi-
ciency in mice leads to embryonic lethality [56],
whereas SMAD3 knockout animals are viable but
display variable reproductive, musculoskeletal, and im-
mune abnormalities depending on genetic background
[57-59]. The selective knockdown of SMADs in cell
lines revealed that SMAD2 and SMAD3 can be
redundant, synergistic, or antagonistic depending on
the studied genes [60-62], but the factors that
determine the relative contributions of SMAD2 and
SMAD3 downstream of the TGF-bR are unknown.
Activation of TGF-bR can also trigger other
signaling pathways independent of the SMADs, such
as mitogen-activated protein kinase, phosphatidylino-
sitol 3 kinase, protein phosphatase 2A, the rho family
of guanosine triphosphatase, and partitioning defective
6 pathways [63]. Some of this versatility of TGF-bR
derives fromTGF-bRII’s ability to also autophosphor-
ylate tyrosine residues, leading to the recruitment
of SH2-domain proteins that can serve as scaffolding
proteins for the activation of alternative pathways
[64,65].
The TGF-b/SMAD pathway can be antagonized
at several levels, including receptor internalization/
degradation, blockade of SMAD protein binding to
the TGF-bR or to nuclear cofactors, and posttransla-
tional SMAD modifications [66]. Of particular note,
TGF-b signaling is subjected to negative feedback
through SMAD7 induction [67]. SMAD7 is structur-
ally related to SMAD2 and SMAD3 but lacks a DNA
interaction domain. It competes with SMAD2 and
SMAD3 for access to the TGF-bR and cooperates
with the ubiquitin ligase Smad ubiquitin regulatory
factor-2 to promote TGF-bR degradation. In addition
to its role in a negative feedback loop, SMAD7 is in-
duced by proinflammatory cytokines, such as IFN-g
[68], TNF-a [69], and IL-6 [70], thus antagonizing
tolerogenic TGF-b signaling.
The spectrum of effects mediated downstream of
the TGF-bR is articulated by the intrinsic versatility
of SMAD-mediated transcription, the use of alterna-
tive signaling pathways, and the integration of other
signals from the cell and tissue environment. How
these various influences on TGF-b signaling intersect
with the complex physiology of the GVH and GVT
reactions remains ill-defined; however, animal
models and human studies indicate that TGF-b is
a key regulator of GVHD and GVT responses.TGF-b AND GVHD
The manifestations of GVHD are extremely vari-
able and have been traditionally segregated according
to the timing of onset after AHCT. Typically, acute
GVHD (aGVHD) occurs within the first 100 days
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inflammatory infiltrate and epithelial cell apoptosis in
one or more of 3 target organs: liver, skin, and
gastrointestinal (GI) tract [71]. Beyond the first 100
days, the manifestations of GVHD in its chronic
form (cGVHD) can include other organ systems,
such as the lungs, mucosal surfaces, and salivary and
lacrimal glands, as well as musculoskeletal structures.
In cGVHD, as opposed to aGVHD lesions, the target
tissues often display prominent sclerotic or fibrotic
changes along with chronic inflammatory changes
[72]. The consequences of pathological tissue remod-
eling in the skin, GI tract, genitourinary tract, and
lungs are responsible for a significant percentage of
the morbidity associated with GVHD. Skin involve-
ment can restrict movement and lead to joint contrac-
tures [73], and sclerosis of fibrotic lesions can be found
along the entire GI tract, from the oral mucosa and sal-
ivary glands (and associated ducts) to the esophagus or
bowel. Strictures and webs, as well as malabsorption
and chronic diarrhea, can supervene in cases of intrac-
table cGVHD [74]. Fibrotic gynecologic complica-
tions include sclerosing vaginitis and stricture
formation [75]. Finally, pulmonary cGVHD leads to
bronchiolitis obliterans, a process associated with
small airway obliteration by fibrosis [76,77].
Over the last decade, however, it has become evi-
dent that a strict distinction between aGVHD and
cGVHD based on the timing of onset post-AHCT
was untenable, given that acute manifestations can
occur well beyond the 100-day mark [5]. A distinction
made on the basis of the underlying immune patho-
physiology might emerge as a more useful way to
distinguish the 2 processes. For aGVHD, a 3-phase
model has been proposed (Figure 1) [71]. Initially,
the conditioning regimen induces tissue damage,
which leads to the release of mediators, such as adeno-
sine triphosphate and uric acid, as well as the translo-
cation of bacteria-derived products, such as
lipopolysaccharide, from the injured intestinal barrier.
These molecules activate host antigen-presenting cells
that can efficiently stimulate alloreactive donor-type
T cells in the second phase. In a third, effector phase,
activated T cells migrate to GVHD target organs and
initiate an antihost inflammatory response that in-
volves the recruitment of other myeloid and lymphoid
immune cells. This 3-phase model can explain most of
the pathophysiological features of aGVHD in both
animal models and in humans. In contrast to aGVHD,
the pathogenesis of cGVHD is poorly understood
[71,72], perhaps due to the great clinical
heterogeneity in both mouse models and humans.
However, cGVHD has several features that can
explain most, if not all, of its clinical manifestations,
including poor thymic function, leading to a failure
to efficiently delete autoreactive donor-type T cells
that develop from marrow progenitors, autoantibodygeneration, and Treg deficiency [78]. Several lines of
evidence now suggest that TGF-b is a key modulator
of both the alloresponse leading to aGVHD and the
pathological manifestations (especially the fibrotic
changes) of cGVHD.
Cytokines are important orchestrators of the
immune response and thus are attractive candidates
for both the study and treatment of GVHD. As a mas-
ter regulator of self-tolerance, TGF-b has been the fo-
cus of several studies in both humans and mice. Serum
TGF-b level fluctuates after AHCT in humans, with
an early decrease in the immediate posttransplantation
period followed by a return to normal range after
3-7 weeks [79]. These changes mirror the initial host
hematolymphoid depletion that supervenes after the
conditioning regimen and the gradual replacement
by donor-derived hematopoietic cells. Serum TGF-
b concentration reportedly decreases in the 2 weeks
preceding the onset of clinical aGVHD [80], and
serum TGF-b level fluctuations might be correlated
with both aGVHD and cGVHD [81]. Whether these
variations contribute to GVHD pathophysiology or
are the consequences of underlying immune-related
processes remains unclear. Decreased serum TGF-
b concentrations in the setting of aGVHD might
contribute to T cell activation but could also be
amere reflection of the hematolymphoid atrophy asso-
ciated with the disease [82,83]. Perhaps a more precise
assessment of TGF-b levels within secondary
lymphoid organs and GVHD target tissues, where
T cell priming and cell-mediated cytotoxicity occur,
respectively, might better define whether TGF-b fluc-
tuations in aGVHD precede or follow the immune
response. Nonetheless, variations in TGF-b serum
concentration might eventually serve as a biomarker
to predict aGVHD onset and guide the early adminis-
tration of immunosuppressive treatments.
Genetically determined variations in the response
to TGF-b have been shown to affect antimicrobial im-
munity [84]. Similarly, gene polymorphisms in TGF-
b and TGF-bRII have been associated with aGVHD
incidence in some case series [85,86]. The results of
a gene expression study in humans revealed that the
pretransplantation expression of a TGF-b pathway
signature in donor T cells was associated with
a decreased incidence of both aGVHD and cGVHD
in recipients [87]. Notably, a low level of SMAD3
transcripts in donor T cells pre-AHCT could predict
the occurrence of GVHD in recipients. However,
how the interindividual differences in TGF-b–related
gene expression interface with the observed fluctuations
of TGF-b posttransplantation and the pathophysiology
of both aGVHD and cGVHD remains unclear.
In a landmark study, Hill and colleagues [88]
showed that antibody-mediated TGF-b neutralization
could either attenuate or exacerbate GVHD depend-
ing on the underlying pathophysiology. Using an
Figure 1. The multiple effects of TGF-b in GVHD pathophysiology. Graphic summary of acute and chronic GVHD pathogenesis highlighting the in-
fluence of TGF-b at multiple key steps. Green circles represent the anti-GVHD properties of TGF-b, and red triangles represent the effects of TGF-
b contributing to GVHD development or end-organ damage. Question marks (?) represent important properties of TGF-b in T cell differentiation
that have yet to be implicated as TGF-b–related in GVHD pathophysiology. LPS, lipopolysaccharide; iDC, immature dendritic cells; mDC, mature den-
dritic cells; ROS, reactive oxygen species.
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aGVHD, they demonstrated that neutralization of
TGF-b early after AHCT increased T cell expansion,
resulting in aGVHD end-organ damage. Importantly,
the main source of TGF-b in the aGVHD model was
the alloreactive T cells themselves, highlighting the
importance of autocrine TGF-b production in
restraining T cell activation [89]. However, delayed
TGF-b blockade in the B10.D2 into Balb.c cGVHD
model was found to ameliorate GVHD scores, in
part secondary to decreased end-organ fibrosis. The
B10.D2 into Balb.c model reproduces the skin thick-
ening as well as the GI and lung fibrosis that are
observed in human cGVHD and systemic sclerosis.
In this model, fibrosis occurs rapidly after trans-
plantation (well before the 100-day mark) and depends
on TGF-b production by myeloid cells. In an earlier
study, McCormick et al. [90] similarly showed that
early TGF-b neutralization attenuated the fibrotic
changes and organ damage using the same donor/
recipient strains. Despite discrepant results regarding
the optimal timing of TGF-b neutralization after
transplantation (likely resulting from methodological
differences between the 2 studies), common findings
emerged. Both studies revealed that TGF-bneutralization ameliorated skin and lung fibrosis and
identified CD11b1 myeloid cells as the main cellular
subset associated with the histopathological lesions.
Therefore, the effects of TGF-b blockade may depend
more on the underlying pathophysiology (lymphoid
versus myeloid-driven disease) than on timing
post-AHCT (Figure 1).
TGF-b’s versatility derives largely from the diver-
sity of its signaling pathways. The relative contribu-
tions of the specific pathways or signaling molecules
downstream of the TGF-bR to GVHD phenotypes
remain ill-characterized. Perhaps an evenmore impor-
tant question is whether the selective targeting of spe-
cific pathways could separate the paradoxical effects of
TGF-b in aGVHD and cGVHD. The pretransplanta-
tion level of SMAD3 transcript expression in donor
T cells has been shown to predict for the occurrence
of both aGVHD and cGVHD in humans [87]. This
finding resonates well with the fact that in T cells
and the hematopoietic system in general, SMAD3
appears to be the dominant downstream mediator of
TGF-b signaling [91]. We used SMAD3-deficient
donors in an MHC-matched, minor histocompatibil-
ity antigen-mismatched mouse model of aGVHD
(129 into Balb.b) to evaluate the specific role of
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wild-type and SMAD3-deficient littermates had similar
hematolymphoid compartments, with no signs of
autoinflammation pre-AHCT. Although a low dose of
wild-type donor splenocytes failed to induce discernible
GVHD, grafts from their SMAD3-deficient littermates
caused fatal disease, owing mostly to colon involvement
by a Th1-biased CD4 and neutrophilic infiltrate. Of
note, both SMAD3-deficient T cells and myeloid cells
were required to cause fatal GVHD. Moreover,
antibody-mediated depletion of neutrophils alleviated
GVHD-related weight loss and histopathological
findings in the colon.
In vitro studies have identified a cell-intrinsic role
for SMAD3 in relaying the TGF-b signals pertaining
to the inhibition of CD4 T cell proliferation and
Th1 skewing, as well as limitation of myeloid cell
expansion and cytotoxicity. Pending confirmation in
other models or in humans, SMAD3’s contribution
to Th1 restriction and CD4 proliferation may repre-
sent a cardinal function of TGF-b in the prevention
of aGVHD. Furthermore, the unexpected finding
that neutrophil-mediated cytotoxicity could be altered
in a SMAD3-dependent manner raises the possibility
that TGF-b controls myeloid cell inflammatory prop-
erties in aGVHD [93]. To date, SMAD3-deficient
donors have not been used in cGVHD models, but
SMAD3 appears to articulate the profibrotic proper-
ties of TGF-b, notably by stimulating collagen synthe-
sis by fibroblasts [94]. Thus, SMAD3 likely contributes
to both the anti- and pro-GVHD effects of TGF-b.
These findings support the notion that clearer knowl-
edge of the underlying pathophysiological context is
needed tomaximize the benefits and limit the potential
harm of targeting TGF-b or SMAD3 in the clinic.
Whether TGF-b signaling differentially regulates
GVHD outcomes in particular tissues remains unre-
solved. Although TGF-b was identified as a central
mediator of GI immune homeostasis in several models
of colitis [95-97], not all AHCTmouse models support
a protective role for TGF-b signaling in gut aGVHD
[88]. In animal models of cGVHD, TGF-b has been
shown to contribute to end-organ fibrosis in the skin,
liver, GI tract, and lungs, likely through local effects.
Sclerotic cGVHD skin biopsy specimens contained
high levels of TGF-b gene transcripts compared with
aGVHD skin lesions, in accordance with the presumed
role of TGF-b in dermal fibrogenesis. aGVHD is
a known risk factor for the development of cGVHD.
The reasons for this are not clear but may pertain
to both the profound disturbances that occur in lym-
phoid tissue homeostasis, notably in the thymus, as
a consequence of aGVHD [6,98] and ongoing
inflammation in aGVHD target tissues. Infections can
also trigger both aGVHD and cGVHD by providing
proinflammatory signals [99,100]. In the context of
viral infections in the lung post-AHCT, TGF-b hasbeen shown to inhibit T cell-dependent viral clearance,
leading to severe pneumonitis [101]. Given that a likely
risk factor for the development of pulmonary cGVHD
is the occurrence of viral infections after transplanta-
tion, TGF-b might indirectly foster the development
of this dreaded complication [76].
Overall, the bulk of the available evidence strongly
suggests that TGF-b inhibits aGVHD, principally
through immunoregulatory effects on conventional
alloreactive T cells. However, the effects of TGF-b
on other cell types have also been shown to affect
aGVHD occurrence and severity. The T cell-
dependent alloresponse relies on antigen presentation
by recipient-type antigen-presenting cells. The expo-
sure of recipient-type dendritic cells to TGF-b ex vivo
followed by their infusion before AHCT has been
shown to prevent aGVHD in mice [102]. Moreover,
the importance of TGF-b in Treg induction is well
known, and Tregs are potent suppressors of GVHD
induction [103,104]. How the variables of Treg
number and function, TGF-b signaling, and
aGVHD pathogenesis are interrelated remains
incompletely defined. The role of Th17 cells,
a TGF-b–dependent subset, on GVHD outcomes is
also a matter of debate. Although most evidence
derived from experimental models supports the
notion that Th17 cells contribute to GVHD,
particularly in the skin and lungs [105,106], the use
of IL-17–deficient donors has been shown to have
modest [107] or detrimental [108] effects on GVHD
outcomes. Other lymphoid subtypes, such as NK and
NK T cells, can suppress aGVHD through various
mechanisms, including the secretion of TGF-
b [109,110]. Likewise, mesenchymal stem cells,
which can be used in the treatment of aGVHD, have
been shown to be potent TGF-b producers [111]. In
cGVHD,TGF-b is no longer protective and in fact ac-
tively contributes to end-organ fibrosis. Analogous to
what is observed in other chronic inflammatory condi-
tions resulting in fibrosis [112], the clinical cGVHD
outcomes likely reflect a failure to resolve ongoing im-
mune responses. The consequences of tissue injury
may translate into the recruitment, activation, and pro-
duction of TGF-b by myeloid cells. However, TGF-
b can suppress the secretion of inflammatory cytokines
and contribute to the resolution of inflammation [113].
Moreover, knowing that the induction of Tregs might
contribute to the mitigation of cGVHD [114,115], we
can ask whether TGF-b contributes to Treg induction
or function in this setting [116]. Such a role of TGF-b
in cGVHD has not been shown, however.TGF-b AND THE GVT EFFECT
The incidence of hematopoietic malignancy re-
lapse after AHCT is inversely related to the presence
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decreased relapse rate in patients with GVHD is one
of the best pieces of evidence supporting the existence
of an alloresponse against neoplastic cells. Despite in-
disputable successes, the strength of the GVT effect
must be put into perspective. It is sobering to note
that disease progression or relapse remains the princi-
pal cause of treatment failure after AHCT [118,119]
and that hematopoietic cancers display variable
sensitivity to the GVT effect, with high-grade
lymphoid malignancies generally less sensitive than
myeloid malignancies [120].
It is well known that TGF-b is abundant in the
microenvironment of several hematopoietic and non-
hematopoietic cancers [7,121]. The effects of TGF-b
in cancer microenvironments are complex and extend
beyond the scope of this review. In fact, TGF-b has
broad-ranging effects on neoplastic cells themselves,
as well as on stromal and infiltrating immune cells
[7,121,122]. The direct effects of TGF-b pathway
signaling on malignant cells are manifold and change
significantly as the cancer cells evolve. Early in the
process of cancer development, TGF-b acts as an
‘‘extrinsic’’ tumor suppressor by transcriptionally
repressing growth-promoting transcription factors,
such as Myc and by up regulating cell-cycle inhibitors,
such as p21, thereby blocking the cell cycle in the G1
phase [123,124]. However, cancer cells evolve
strategies to bypass the TGF-b inhibitory signals as
they progress. This is often achieved by mutating
genes involved in the TGF-b signaling pathway,
increasing competing pathway activity or directly
overexpressing oncogenes repressed by TGF-b, such
as Myc [122]. Moreover, not all sensitivity to TGF-
b is lost as malignancies progress. Partly because of
the great versatility of TGF-b signaling, many cancer
cells retain some TGF-b responsiveness; for example,
TGF-b–dependent epitheliomesenchymal transition
favors the transition of epithelial cancer cells to
mesenchymal-like cells with increased motility and
a greater propensity to metastasize [125,126]. In
addition, TGF-b signaling in advanced cancers can
promote cell survival [127].
Along with being a major player in tumor cell
biology,TGF-bhas also been found to act on accessory
cells that compose the cancer microenvironment.
Deficient TGF-b signaling in fibroblasts contributes
to tumor growth in a variety of models [128] and,
although incompletely understood, TGF-b and
TGF-bR are likely involved in several aspects of cancer
neoangiogenesis [129]. Finally, TGF-b blunts the
natural immune response to cancer by several
mechanisms, including the recruitment of regulatory
cells, such as Tregs and myeloid-derived suppressor
cells, and, as discussed earlier, by directly antagonizing
efficient antigen presentation and cytotoxic mecha-
nisms [121].The targets of GVT effects in clinical AHCT are
hematopoietic malignancies, many of which produce
TGF-b or evolve in a TGF-b–rich milieu [130-133].
For example, excess TGF-b signaling has been
incriminated for causing the intense fibrotic reaction
that supervenes in myelofibrosis [134] and nodular
sclerosing Hodgkin disease [135]. These examples of
overexuberant TGF-b signaling in malignant hemato-
poietic and lymphoid milieus underscore the close
relationship between blood cells and TGF-b. In fact,
TGF-b is a key regulator of hematopoietic cell biology,
with significant contributions to stem cell maintenance
and the control of cell proliferation [91,136,137]. The
importance of the TGF-b pathway to hematopoietic
cell homeostasis is further demonstrated by the
compromised TGF-b signaling seen as a consequence
of specific genetic alterations in neoplastic cells
[133,138-141]. Given the prominent role of TGF-
b in both cell-intrinsic and cell-extrinsic processes re-
lated to physiological or neoplastic hematopoiesis, we
can raise the question whether TGF-b limits the po-
tency of the GVT effect. Several investigators have
shown that targeting TGF-b production or signaling
increased the potency of various anticancer immuno-
therapy approaches in animal models [142,143].
Notably,Gorelik andFlavell [144] reported thatT cells
expressing a dominant negativeTGF-bR (dnTGF-bR)
could successfully prevent the development of EL4
lymphoma and B16 melanoma in mice. Accumulating
preclinical data have prompted the development of
multiple anti–TGF-b biopharmaceuticals now under
evaluation in clinical trials (reviewed in [142]). Studies
specifically evaluating the role of TGF-b in the GVT
effect are scarce; however, one study has proposed
that alloreactivity against the TS/A Balb.c murine
breast cancer model is modulated in a TGF-b depen-
dentmanner [145].The abrogationofTGF-b secretion
by the tumor cells afterTGF-b1 antisense vector trans-
fection resulted in high tumor rejection post-AHCT
compared with no evidence of a GVT effect against
mock-transfected cells. These results are compatible
with the idea that TGF-b is a determining intratumor
modulator of anticancer immune responses. In con-
trast, in their seminal observations, Hill and colleagues
[88] showed that antibody-mediated TGF-b neutrali-
zation in mice not only accentuated aGVHD, but, sur-
prisingly, also attenuated the GVT effect against an
injectable hematopoietic cancer. This seemingly para-
doxical effect on theGVTeffectmight be related to the
intricacies of the model (a CD4 T cell-dependent
GVHD process and a CD8 T cell-dependent GVT ef-
fect, as suggested by the authors). Other possible con-
tributing factors include a loss of the homeostatic
effects of TGF-b directly onT cells themselves or indi-
rectly, through the modulation of aGVHD-related in-
flammation. Hill and colleagues reported increased
apoptotic rates of both CD4 and CD8 T cells after
Table 1. Summary of Strategies to Enhance the GVT Effect
Modalities Mode of Action Localization/Target
Plausible Impact on
aGVHD cGVHD GVT
Anti–TGF-b antibodies Ligand neutralization Systemic [ Y [
Pharmacologic inhibitors Inhibition of TGF-b signaling Systemic [ Y [
Genetic modification of T cells
(expression of a dnTGF-bR)
Disruption of TGF-b signaling,
antigen specificity
Tumor-specific 4 4 [
dnTGF-bR indicates dominant-negative TGF-b receptor.
1336 Biol Blood Marrow Transplant 18:1329-1340, 2012C. Carli et al.TGF-b blockade, consistent with findings in other
models, indicating that severe aGVHD-related inflam-
mation promotes T cell dysfunction and death that can
impede the GVT effect [82,146,147]. Thus, systemic
TGF-b neutralization or signaling blockade in
clinical AHCT could be fraught with the perils of
enhancing aGVHD without inducing a concomitant
GVT effect. Alternative approaches to achieving
specific TGF-b signaling blockade in immune cells
within cancer environments are emerging, however.
Using Epstein-Barr virus-related posttransplantation
lymphoma, a high-grade and TGF-b–rich B cell
neoplasm, as a model, Bollard and coworkers
[148,149] have shown that T cells engineered to
express a dnTGF-bR and selected for their specificity
against EBV antigens have more potent antilymphoma
activity than unmodified cells. Considering that EBV-
specific T cells do not cause GVHD, even in the setting
of partial donor-recipient HLA matching in humans
[150], this pioneering approach might soon be applica-
ble to other types of targets, such as tumor-associated
antigens [151,152] and immunodominant minor
histocompatibility antigens [153,154].
AlongwithT lymphocytes,NKcells have also been
shown to exert potent anticancer effects.The transcrip-
tion of IFN-g and otherNK cell cytotoxicmechanisms
are antagonized by the TGF-b/SMAD3 axis [25,155].
The possibility that NK cells could mediate an
antimyeloid leukemia effect in HLA-haploidentical
AHCT [156] raises the prospect that targeting
TGF-b concomitantly with NK cell alloreactivity
could enhance antileukemic responses. Haploidentical
AHCTcarries a low incidence ofGVHD, because ofT
cell depletion from the graft; thus, it could serve as an
ideal platform to introduce TGF-b inhibition
approaches in AHCT, with the aim of maximizing
NK-dependent GVT without causing GVHD. The
different approaches to antagonizing TGF-b signaling
in neoplastic milieus are summarized in Table 1.CONCLUSION AND PERSPECTIVES
The hematopoietic system and TGF-b are inter-
twined in both physiological and pathological con-
texts. As a master regulator of immune tolerance,
TGF-b modulates all immunologically relevant
outcomes in experimental AHCT, including GVHDand the GVT effect. Although TGF-b inhibits the de-
velopment of aGVHD, it contributes to tissue damage
in cGVHD. Therefore, a clear knowledge of the
underlying pathophysiology is needed before any ther-
apeutic interventions aiming at manipulating TGF-
b signaling in clinical GVHD are considered. Another
consideration is whether manipulation of TGF-b sig-
naling can be more specific, restricted to certain cell
types, or spatially limited to certain organs or tissues.
We have proposed a protective role for the TGF-b/
SMAD3 signaling axis in GI GVHD. Local TGF-
b signaling locally in the gut might be enhanced by al-
tering themicroflora [157] in an attempt to limit one of
the most morbid complications of aGVHD [158]. In
cGVHD, several pharmacologic TGF-b signaling in-
hibitors could be used to limit fibrotic complications,
with or without the anti–platelet-derived growth fac-
tor approaches currently under investigation for this
purpose [159]. Whether the administration of such
molecules would have an impact on neoplastic relapse
in cGVHD needs to be monitored. Available experi-
mental models have provided invaluable insight into
the mechanisms of the GVT effect occurring early
after AHCT; however, none can recapitulate the epi-
demiologically demonstrated association between
cGVHD and lower rates of relapse. Whether TGF-
b plays any role in modulating the GVT effect during
cGVHD remains an open question.
In recent years, various investigators have charac-
terized the immune environment of human cancers
[121,142,160,161]. Both the type of infiltrating
immune cells and the pattern of infiltration were
found to have a major prognostic impact in several
types of malignancies. The features of the cancer
microenvironment that could influence the outcome
of AHCT-based adoptive immunotherapy are a matter
of speculation. Given the close relationship between
TGF-b and hematopoiesis as well as hematopoietic
cancers, local TGF-b production can have important
effects on both malignant myeloid and lymphoid cell
biology and their microenvironment. Moreover, after
AHCT, the presence of TGF-b could mitigate the
GVT effect by inhibiting immune cells. The demon-
strated activity of antigen-specific, genetically modi-
fied dnTGF-bR T cells against several types of
malignancies is encouraging. This strategy delivers po-
tent T cell effectors within tumor beds and avoids the
Biol Blood Marrow Transplant 18:1329-1340, 2012 1337TGF-b in Allogeneic Cell Transplantationrisk of systemic TGF-b neutralization. The targeted
inhibition of TGF-b in space and timemight definitely
turn the tide in favor of GVT without increasing the
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